---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-267402"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:53:46.687844+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Aardvark Therapeutics reviews ARD-101 and ARD-201 programs at investor webinar; no new data disclosed

## Summary
- Filed presentation lacks specific clinical results or financial figures.
- Webinar covered ARD-101 and ARD-201 programs and ObesityWeek 2025 presentations.
- Materiality is limited as filing is a procedural update without substantive new information.

## SEC filing metadata
- accession: 0001193125-25-267402
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312525267402/0001193125-25-267402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312525267402/ck0001774857-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-267402
- JSON: https://secwatch.observer/filing/0001193125-25-267402.json
- Plain text: https://secwatch.observer/filing/0001193125-25-267402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.